Skip to content

Segmentectomy vs Lobectomy

Different Segmentectomy vs Lobectomy Comparison in NSCLC

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06180239
Enrollment
800
Registered
2023-12-22
Start date
2017-01-01
Completion date
2024-12-31
Last updated
2023-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer Stage I, Surgery

Keywords

segmentectomy, lobectomy

Brief summary

Actual indications for stage Ia NSCLC patients suggest lobectomy and lymphadenectomy. On the other hand, recent studies reported non-inferiority of segmentectomy in case of nodule \< 2cm or with ground glass appearance at computed tomography. However, most of these studies did not report specifical analysis on kind of segmentectomy (single or multiple) and kind of lobectomy. Moreover, a specific study on solid nodules only is still missing. For these reasons, the effectiveness of segmentectomy instead lobectomy for every kind of segment or tumor is still to be defined. Aim of this study is to analyze survival outcome in patients underwent single or multiple segmentectomy compared to lobectomy in stage I non small cell lung cancer.

Interventions

None listed

Sponsors

Regina Elena Cancer Institute
CollaboratorOTHER
Istituto Europeo di Oncologia
CollaboratorOTHER
University of Pisa
CollaboratorOTHER
A.O.U. Città della Salute e della Scienza - Molinette Hospital
CollaboratorOTHER
Azienda Ospedaliera Sant'Andrea
CollaboratorOTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adenocarcinoma or squamous cell carcinoma * cStage cIA with or without nodal upstaging * lymphoadenectomy * age \> 18 years old * Radical resection * anatomical resection (lobectomy or segmentectomy) * PET CT done

Exclusion criteria

* Nodal or distant metastasis confirmed before surgery * Pure solid GGO * Follow up \< 12 months * Bilobectomy/pneumonectomy * Trans fissure tumor * Multiple lung tumors

Design outcomes

Primary

MeasureTime frameDescription
disease free survival1 YEARTime between surgery and recurrence appearance

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026